PharmExec Direct: Having trouble viewing the email? Click Here

In this ISSUE

Rooting Out Pharma Corruption

The Vicious Circle of EU Drug Pricing

2016 Emerging Pharma Leaders — Nominate Now

Advertisement
Regulatory
FDA to Address Opioid Trial Challenges
FDA is under tremendous pressure to do more to address the national epidemic of opioid abuse that is causing thousands of deaths and medical emergencies. While patients and providers demand effective treatments for chronic and acute pain, the public wants safeguards to prevent overdosing and misuse of these products, writes Jill Wechsler.
... /Read more/
 
Regulatory
What “Precision Medicine” Means for Rare Diseases
President Obama’s year-old, $200 million Precision Medicine initiative (PMI) seems to be doing exactly what was intended, writes Heather Gartman
... /Read more/
 
Advertisement
The ZS Explorer Study finds that pharma investments in sales force effectiveness boost revenue 1 - 7%. That might not sound like much, but given their size and scale, pharmacos can achieve a substantial return on sales force effectiveness investments.
Read the report to see the latest data on pharma sales force effectiveness.
 
Emerging Pharma Leaders
Pharm Exec’s Emerging Pharma Leaders 2016 — Nominate Now
Pharm Exec is looking for the fresh faces of pharma leadership. And we'd like your input. Tell us who you think should be included as one of our 2016 Emerging Pharma Leaders. These leaders are vital to the future of the industry, and you can help ensure they get the recognition they deserve. Fill out your nomination today
... /Read more/
Opinion
How Did Things Get This Bad? Look in the Mirror, US Pharma
As US pharma continues to ponder its “winter of discontent” and ask, “How did things get this bad?”, the industry might want to take a long look in the mirror, writes Tom Norton
... /Read more/
 
Advertisement
SPEED TO INSIGHT: 4 Strategies you need to maximize the value of your data assets
ON DEMAND
Join Hewlett Packard Enterprise and Linguamatics as they discuss the right questions to ask about your company's analytics capabilities to gain a competitive advantage.
Learn more
 
Q&A
Genomic Data to Valuable to Hoard
Ambry Genetics' CEO discusses his company's decision to release the genetic information of its customers for free — a rare move, reportedly, for a commercial testing firm
... /Read more/
 
Calendar
/ March 15–17: eyeforpharma 2016 /
Barcelona, Spain
/ March 22–23: 9th Annual Oncology Commercialization and Market Access /
San Francisco, CA.
/ April 18–19: IRT Europe — Interactive Response Technologies in Clinical Trials /
Brussels, Belgium
/ June 21–22: Patient Engagement Solutions Summit /
Philadelphia, PA.
/ August 15–17: 10th Annual Forum on Transparency and Aggregate Spend /
Washington, DC.
 
Industry update
//Accera, Inc. (Broomfield, CO) announced the appointment of Ernest Wong, Ph.D., MBA, as Vice President of Corporate Development.//Immunome (Philadelphia, PA) appointed Michael J. Morin, Ph.D., as President and Chief Scientific Officer.//Illumina, Inc. (San Diego, CA) announced that Jay Flatley, current Chairman and CEO, will assume the role of Executive Chairman of the Board of Directors on July 5, 2016. Francis deSouza, currently President, will be appointed President and Chief Executive Officer on the same date and will continue to serve on the Illumina Board of Directors.//Merck (Kenilworth, NJ) appointed Sanat Chattopadhyay as Executive Vice President and President, Merck Manufacturing Division (MMD), effective April 1, 2016. Chattopadhyay will succeed Willie A. Deese who will retire on June 1, 2016 after 12 years with the company.//
 
advertise with us / print subscribe / digital subscribe / visit pharmexec.com